These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25670516)

  • 1. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
    Rice AS; Smith MT
    Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.
    Anand U; Yiangou Y; Sinisi M; Fox M; MacQuillan A; Quick T; Korchev YE; Bountra C; McCarthy T; Anand P
    Mol Pain; 2015 Jun; 11():38. PubMed ID: 26111701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
    Smith MT; Muralidharan A
    Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
    Smith MT; Wyse BD; Edwards SR
    Pain Med; 2013 May; 14(5):692-705. PubMed ID: 23489258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.
    Shepherd AJ; Rice AS; Smith MT
    Curr Opin Pharmacol; 2023 Dec; 73():102415. PubMed ID: 38041933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.
    Smith MT; Anand P; Rice ASC
    Pain; 2016 Feb; 157 Suppl 1():S33-S41. PubMed ID: 26785154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
    Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
    Muralidharan A; Wyse BD; Smith MT
    Pain Med; 2014 Jan; 15(1):93-110. PubMed ID: 24433468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
    McCarthy T
    J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2():S13-4. PubMed ID: 25269730
    [No Abstract]   [Full Text] [Related]  

  • 10. A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.
    Smith MT; Woodruff TM; Wyse BD; Muralidharan A; Walther T
    Pain Med; 2013 Oct; 14(10):1557-68. PubMed ID: 23742186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug treatment reduces chronic pain following shingles.
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):180-1. PubMed ID: 25011130
    [No Abstract]   [Full Text] [Related]  

  • 12. EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome.
    Nozu T; Miyagishi S; Nozu R; Ishioh M; Takakusaki K; Okumura T
    J Pharmacol Sci; 2021 Jul; 146(3):121-124. PubMed ID: 34030794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the angiotensin II type 2 receptor AT
    Perryman R; Renziehausen A; Shaye H; Kostagianni AD; Tsiailanis AD; Thorne T; Chatziathanasiadou MV; Sivolapenko GB; El Mubarak MA; Han GW; Zarzycka B; Katritch V; Lebon G; Lo Nigro C; Lattanzio L; Morse SV; Choi JJ; O'Neill K; Kanaki Z; Klinakis A; Crook T; Cherezov V; Tzakos AG; Syed N
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2116289119. PubMed ID: 35917342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New investigational drugs for the treatment of neuropathic pain.
    Sałat K; Kowalczyk P; Gryzło B; Jakubowska A; Kulig K
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1093-104. PubMed ID: 24896842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage angiotensin II type 2 receptor triggers neuropathic pain.
    Shepherd AJ; Mickle AD; Golden JP; Mack MR; Halabi CM; de Kloet AD; Samineni VK; Kim BS; Krause EG; Gereau RW; Mohapatra DP
    Proc Natl Acad Sci U S A; 2018 Aug; 115(34):E8057-E8066. PubMed ID: 30082378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist.
    Murgasova R; Carreras ET; Suetterlin-Hachmann M; da Silva Torrao LR; Kittelmann M; Alexandra V; Fredenhagen A
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):166-183. PubMed ID: 32190910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy.
    Rice ASC; Dworkin RH; Finnerup NB; Attal N; Anand P; Freeman R; Piaia A; Callegari F; Doerr C; Mondal S; Narayanan N; Ecochard L; Flossbach Y; Pandhi S
    Pain; 2021 Oct; 162(10):2578-2589. PubMed ID: 33675631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy.
    Smith MT; Lau T; Wallace VC; Wyse BD; Rice AS
    Behav Pharmacol; 2014 Apr; 25(2):137-46. PubMed ID: 24525712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of Unevoked Mechanical and Cold Pain Hypersensitivities Associated With Experimental Neuropathy in Mice by Angiotensin II Type-2 Receptor Antagonism.
    Shepherd AJ; Mohapatra DP
    Anesth Analg; 2019 Jun; 128(6):e84-e87. PubMed ID: 31094778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?
    Bouhassira D; Attal N
    Pain; 2018 Mar; 159(3):576-582. PubMed ID: 29447137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.